BR112018076169A2 - derivados azabenzimidazol como inibidores de pi3k beta - Google Patents
derivados azabenzimidazol como inibidores de pi3k betaInfo
- Publication number
- BR112018076169A2 BR112018076169A2 BR112018076169-9A BR112018076169A BR112018076169A2 BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2 BR 112018076169 A BR112018076169 A BR 112018076169A BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2
- Authority
- BR
- Brazil
- Prior art keywords
- beta inhibitors
- pi3k beta
- azabenzimidazole derivatives
- compounds
- azabenzimidazole
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174712 | 2016-06-16 | ||
| EP16174712.6 | 2016-06-16 | ||
| PCT/EP2017/064672 WO2017216293A1 (en) | 2016-06-16 | 2017-06-15 | Azabenzimidazole derivatives as pi3k beta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018076169A2 true BR112018076169A2 (pt) | 2019-03-26 |
Family
ID=56132833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018076169-9A BR112018076169A2 (pt) | 2016-06-16 | 2017-06-15 | derivados azabenzimidazol como inibidores de pi3k beta |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190263804A1 (https=) |
| EP (1) | EP3472147B1 (https=) |
| JP (1) | JP7158286B2 (https=) |
| KR (1) | KR102472198B1 (https=) |
| CN (1) | CN109311843B (https=) |
| AU (1) | AU2017286380B2 (https=) |
| BR (1) | BR112018076169A2 (https=) |
| CA (1) | CA3025746A1 (https=) |
| EA (1) | EA037871B1 (https=) |
| ES (1) | ES2818620T3 (https=) |
| IL (1) | IL263653A (https=) |
| MX (1) | MX375484B (https=) |
| WO (1) | WO2017216293A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3904350T3 (da) | 2018-04-12 | 2023-11-13 | Bayer Ag | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamidderivater og de tilsvarende pyridincarboxamidderivater som pesticider |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| MX2020011275A (es) | 2018-04-25 | 2020-11-13 | Bayer Ag | Novedosos compuestos de heteroaril-triazol y hetroaril[-]tetrazol como plaguicidas. |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| US20220274947A1 (en) | 2019-07-23 | 2022-09-01 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
| CN110551101B (zh) * | 2019-08-28 | 2020-11-24 | 沈阳药科大学 | 1、6-二取代-苯并五元杂环类衍生物及其用途 |
| TW202128664A (zh) | 2019-10-09 | 2021-08-01 | 德商拜耳廠股份有限公司 | 作為除害劑之新穎雜芳基三唑化合物 |
| JP2023512204A (ja) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| US20230131192A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US12485123B2 (en) | 2020-01-27 | 2025-12-02 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
| KR20220132601A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| CN115151546A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物 |
| US20230348468A1 (en) | 2020-01-27 | 2023-11-02 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132589A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
| WO2021154663A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20230144824A1 (en) | 2020-01-27 | 2023-05-11 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| US20250382289A1 (en) * | 2022-02-18 | 2025-12-18 | Xizang Haisco Pharmaceutical Co., Ltd. | Pyrazolopyridine derivative and application thereof in medicine |
| WO2024222880A1 (zh) * | 2023-04-27 | 2024-10-31 | 西藏海思科制药有限公司 | 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177074A (en) * | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| EP1993537A4 (en) | 2006-03-02 | 2010-05-19 | Glaxosmithkline Llc | THIAZOLONES AS INHIBITORS OF P13-KINASES |
| WO2008014219A2 (en) | 2006-07-24 | 2008-01-31 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as p13 kinase inhibitors |
| WO2009021083A1 (en) | 2007-08-09 | 2009-02-12 | Smithkline Beecham Corporation | Quinoxaline derivatives as pi3 kinase inhibitors |
| BRPI0817503B8 (pt) * | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
| EP3613743B1 (en) | 2008-01-04 | 2022-03-16 | Intellikine, LLC | Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| KR20120081164A (ko) | 2009-09-29 | 2012-07-18 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | Ｐｉ3ｋ(델타) 선택적 억제제 |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| JP5719028B2 (ja) | 2010-10-06 | 2015-05-13 | グラクソスミスクライン エルエルシー | Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体 |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| WO2013095761A1 (en) * | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
-
2017
- 2017-06-15 WO PCT/EP2017/064672 patent/WO2017216293A1/en not_active Ceased
- 2017-06-15 CN CN201780037153.5A patent/CN109311843B/zh active Active
- 2017-06-15 EP EP17729500.3A patent/EP3472147B1/en active Active
- 2017-06-15 MX MX2018015709A patent/MX375484B/es active IP Right Grant
- 2017-06-15 ES ES17729500T patent/ES2818620T3/es active Active
- 2017-06-15 AU AU2017286380A patent/AU2017286380B2/en not_active Ceased
- 2017-06-15 US US16/310,413 patent/US20190263804A1/en not_active Abandoned
- 2017-06-15 JP JP2018565868A patent/JP7158286B2/ja active Active
- 2017-06-15 EA EA201892734A patent/EA037871B1/ru not_active IP Right Cessation
- 2017-06-15 CA CA3025746A patent/CA3025746A1/en active Pending
- 2017-06-15 KR KR1020187037717A patent/KR102472198B1/ko active Active
- 2017-06-15 BR BR112018076169-9A patent/BR112018076169A2/pt not_active Application Discontinuation
-
2018
- 2018-12-11 IL IL263653A patent/IL263653A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN109311843A (zh) | 2019-02-05 |
| MX2018015709A (es) | 2019-03-21 |
| CN109311843B (zh) | 2021-10-08 |
| JP2019518059A (ja) | 2019-06-27 |
| KR102472198B1 (ko) | 2022-11-28 |
| AU2017286380A1 (en) | 2018-12-06 |
| EA037871B1 (ru) | 2021-05-28 |
| MX375484B (es) | 2025-03-06 |
| KR20190016976A (ko) | 2019-02-19 |
| EA201892734A1 (ru) | 2019-05-31 |
| IL263653A (en) | 2019-01-31 |
| AU2017286380B2 (en) | 2021-02-04 |
| EP3472147B1 (en) | 2020-06-17 |
| JP7158286B2 (ja) | 2022-10-21 |
| ES2818620T3 (es) | 2021-04-13 |
| CA3025746A1 (en) | 2017-12-21 |
| EP3472147A1 (en) | 2019-04-24 |
| US20190263804A1 (en) | 2019-08-29 |
| WO2017216293A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076169A2 (pt) | derivados azabenzimidazol como inibidores de pi3k beta | |
| BR112018003595A2 (pt) | análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5 | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| BR112019006414A2 (pt) | análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5 | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| BR112018007068A2 (pt) | derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta | |
| BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
| BR112012017442A2 (pt) | derivados de triazol bicíclicos substituídos como moduladores de gamma secretase | |
| BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
| BR112016006651B8 (pt) | compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR112013023984A2 (pt) | derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| BR112015007183A2 (pt) | composições, uso de uma composição, método para o combate dos fungos e semente | |
| MX2016002185A (es) | Formulacion combinada de dos compuestos antivirales. | |
| BR112015024971A2 (pt) | derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk | |
| BR112017012005A2 (pt) | compostos orgânicos | |
| BR112018011525A2 (pt) | inibidores da tirosina quinase de bruton e métodos de seu uso | |
| DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| MX2016005437A (es) | Derivados de n-(1-hidroxi-3-(pirrolidinil)propan-2-il)pirrolidin-3 -carboxamida como inhibidores de glucosilceramida sintasa. | |
| BR112017012930A2 (pt) | derivados de imidazopiridazina como inibidores de pi3kbeta. | |
| BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |